

# BMJ Open

BMJ Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available.

When an article is published we post the peer reviewers' comments and the authors' responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to.

The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript.

BMJ Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (<http://bmjopen.bmj.com>).

If you have any questions on BMJ Open's open peer review process please email [info.bmjopen@bmj.com](mailto:info.bmjopen@bmj.com)

# BMJ Open

## A protocol for development of a reporting guideline (TRIPOD-AI) and risk of bias tool (PROBAST-AI) for diagnostic and prognostic prediction studies based on artificial intelligence

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2020-048008
Article Type:	Protocol
Date Submitted by the Author:	15-Dec-2020
Complete List of Authors:	Collins, Gary; University of Oxford, Centre for Statistics in Medicine Dhiman, Paula; University of Nottingham, School of Medicine Andaur Navarro, Constanza L.; Julius Center for Health Sciences and Primary Care, Epidemiology Ma, Ji; University of Oxford Hooft, Lotty; University Medical Center Utrecht, University of Utrecht, Cochrane Netherlands Reitsma, Johannes; University Medical Center Utrecht, Julius Center for Health Sciences and Primary Care Logullo, Patricia; University of Oxford Beam, Andrew; Harvard Medical School, Peng, Lily; Google Inc Van Calster, Ben; KU Leuven, Department of Development and Regeneration van Smeden, Maarten; Universiteit Leiden, Riley, Richard; Keele University Moons, Karel; Julius Center for Health Sciences and Primary Care, Epidemiology
Keywords:	STATISTICS & RESEARCH METHODS, EPIDEMIOLOGY, GENERAL MEDICINE (see Internal Medicine)

SCHOLARONE™  
Manuscripts



I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our [licence](#).

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which [Creative Commons](#) licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

# A protocol for development of a reporting guideline (TRIPOD-AI) and risk of bias tool (PROBAST-AI) for diagnostic and prognostic prediction studies based on artificial intelligence

Gary S. Collins<sup>1,2\*</sup>, Paula Dhiman<sup>1,2</sup>, Constanza L. Andaur Navarro<sup>3,4</sup>, Jie Ma<sup>1</sup>, Lotty Hooft<sup>3,4</sup>, Johannes B. Reitsma<sup>3</sup>, Patricia Logullo<sup>1</sup>, Andrew L. Beam<sup>5,6</sup>, Lily Peng<sup>7</sup>, Ben Van Calster<sup>8,9,10</sup>, Maarten van Smeden<sup>3</sup>, Richard D. Riley<sup>11</sup>, Karel G.M. Moons<sup>3,4\*</sup>

<sup>1</sup> Centre for Statistics in Medicine, Nuffield Department of Orthopaedics, Rheumatology & Musculoskeletal Sciences, University of Oxford, Oxford, OX3 7LD, United Kingdom

<sup>2</sup> NIHR Oxford Biomedical Research Centre, John Radcliffe Hospital, Oxford, United Kingdom NIHR Oxford Biomedical Research Centre, John Radcliffe Hospital, Oxford, United Kingdom

<sup>3</sup> Julius Center for Health Sciences & Primary Care, and Cochrane Netherlands, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands

<sup>4</sup> Cochrane Netherlands, University Medical Center Utrecht, Utrecht University, The Netherlands

<sup>5</sup> Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, Massachusetts, United States

<sup>6</sup> Department of Biomedical Informatics, Harvard Medical School, Boston, Massachusetts, United States

<sup>7</sup> Google Health, 3400 Hillview Ave, Palo Alto, CA 94304, United States

<sup>8</sup> KU Leuven, Department of Development and Regeneration, Leuven, Belgium

<sup>9</sup> Department of Biomedical Data Sciences, Leiden University Medical Centre (LUMC), Leiden, the Netherlands

<sup>10</sup> EPI-centre, KU Leuven, Leuven, Belgium

<sup>11</sup> Centre for Prognosis Research, School of Medicine, Keele University, Staffordshire, ST5 5BG, United Kingdom.

\* Both authors contributed equally

Address for correspondence:

Professor Gary S Collins

Centre for Statistics in Medicine

Nuffield Department of Orthopaedics, Rheumatology & Musculoskeletal Sciences

University of Oxford

Oxford, OX3 7LD

United Kingdom.

Email: [gary.collins@csm.ox.ac.uk](mailto:gary.collins@csm.ox.ac.uk)

Twitter: @GSCollins, @CarlMoons

ORCID: [0000-0002-2772-2316](https://orcid.org/0000-0002-2772-2316)

## Abstract

**Introduction:** The Transparent Reporting of a multivariable prediction model of Individual Prognosis Or Diagnosis (TRIPOD) statement and the Prediction model Risk Of Bias ASsessment Tool (PROBAST) were both published to improve the reporting and critical appraisal of prediction model studies for diagnosis and prognosis. This paper describes the processes and methods that will be used to develop an extension to the TRIPOD statement (TRIPOD-AI) and the PROBAST (PROBAST-AI) tool for prediction model studies that applied machine learning techniques.

**Methods and Analysis:** TRIPOD-AI and PROBAST-AI will be developed following published guidance from the EQUATOR Network, and will comprise five stages. Stage one will comprise two systematic reviews (across all medical fields and specifically in oncology) to examine the quality of reporting in published machine-learning based prediction model studies. In stage two we will consult a diverse group of key stakeholders using a Delphi process to identify items to be considered for inclusion in TRIPOD-AI and PROBAST-AI. Stage three will be a virtual consensus meeting to consolidate and prioritise key items to be included in TRIPOD-AI and PROBAST-AI. Stage four will involve developing the TRIPOD-AI checklist and the PROBAST-AI tool, and writing the accompanying explanation and elaboration papers. In the final stage, stage 5, we will disseminate TRIPOD-AI and PROBAST-AI via journals, conferences, blogs, websites (including TRIPOD, PROBAST and EQUATOR Network), and social media. TRIPOD-AI will provide researchers working on prediction model studies based on machine-learning with a reporting guideline that can help them report key details that readers need to evaluate the study quality and interpret its findings, potentially reducing research waste. We anticipate PROBAST-AI will help researchers, clinicians, systematic reviewers and policymakers critically appraise the design, conduct and analysis of machine learning based prediction model studies, with a robust standardised tool for bias evaluation.

## Ethics and Dissemination

Ethical approval has been granted by the Central University Research Ethics Committee (CUREC), University of Oxford on 10-December-2020 (R73034/RE001). Findings from this study will be disseminated through peer review publications.

**Keywords:** prediction, artificial intelligence, machine learning, reporting guideline, risk of bias, TRIPOD, PROBAST

## Article Summary

### Strengths and limitations of this study

- The reporting of clinical prediction models using artificial intelligence is poor.
- There are no guidelines for the reporting or risk of bias assessment of clinical prediction models using artificial intelligence.
- The strengths of this study is that it follows published guidance from the EQUATOR Network for developing reporting guidelines. Expert opinion and consensus will be obtained from multiple stakeholders (statisticians, clinician scientists, epidemiologists, computer scientists, funders, healthcare policy makers, patients, and industry leaders).
- Limitations of this study potentially include representativeness of the Delphi panel as these may differ from those who decline to participate.

## Background

Models that predict clinical outcomes are abundant in the medical literature and are broadly categorised as those that estimate the probability of the presence of a particular outcome (diagnostic) or whether a particular outcome (e.g. event) will occur in the future (prognostic) [1]. Traditionally these models (herein referred to as prediction model) have been developed using regression-based methods, typically logistic regression for short-term outcomes and Cox regression for longer-term outcomes [2]. Numerous reviews have observed that studies describing the development and validation (including updating) of a prediction model often fail to report key information to help readers judge the methods and have a complete, transparent and clear picture of the model's predictive accuracy and other relevant details such as the target population and the content of the model itself [3–6]. The absence of full and comprehensive reporting limits the usability of the findings of these studies, e.g., in subsequent validation studies, evidence synthesis studies, or in daily practice, and therefore contribute to research waste [7]. In response to this, in 2015, the Transparent Reporting of a multivariable prediction model for Individual Prognosis Or Diagnosis (TRIPOD) Statement was published [1, 8]. The TRIPOD Statement is a checklist of 22-items that authors should report with sufficient detail and clarity to inform how the study was carried out.

Since the publication of the TRIPOD Statement, artificial intelligence (AI) and in particular machine learning, approaches to clinical prediction have evolved and grown in popularity with the number of AI and machine learning publications rapidly rising [9–14]. This is evident within a recent review of COVID-19 related prediction models, where 57 (out of 107 included studies) used machine learning methods to develop their model [15].

Machine learning, a branch of artificial intelligence, can be broadly described as data analytical methods that learn from data without being explicitly programmed, with patterns identified based on the data itself. They are often described as having flexibility to capture complex associations particularly in large and unstructured data and complexity in modelling. Whilst the vast majority of the items in the TRIPOD Statement are relevant to machine learning based prediction model studies, there are some unique challenges with machine learning that are not captured. Due to their complexity, these prediction models are typically considered to be 'black box', unlike say regression-based models where the full model can be transparently presented (e.g., as an equation containing all the regression coefficients). Also, whilst many machine learning methods have origins in the statistical literature, two (overlapping) prediction model cultures have emerged as those from a statistical/epidemiological background and those from the computer science/data sciences. Although

1  
2  
3 there is clear overlap, different approaches to model development, validation and updating have  
4 appeared, and different and sometimes conflicting terminology have arisen.  
5  
6  
7

8 Due to the relative novelty of applying machine learning methods to clinical prediction modelling,  
9 there is little information on the quality of reporting of these studies. However, the few reviews that  
10 have examined the completeness of reporting of have concluded that reporting is poor [16, 17]. In  
11 response to these concerns, guidance is required to help authors fully describe their prediction model  
12 study when machine learning methods were used. Therefore the TRIPOD group initiated a large  
13 international project to develop a consensus based extension of TRIPOD with specific focus on  
14 reporting of studies that undertake the development, validation or updating of a diagnostic or  
15 prognostic prediction model, using machine learning techniques – herein referred to as TRIPOD-AI  
16 [18]. The TRIPOD-AI extension, comprising a checklist and an accompanying elaboration and  
17 explanation document will provide researchers, authors, reviewers, editors, users, and other  
18 stakeholders of machine learning based prediction model studies, with guidance on the minimal set  
19 of items to report, with detailed examples of good reporting for each item.  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29

30 Complete reporting allows studies to be understood, replicated and used. However, critical appraisal  
31 and of the quality of study method is a crucial component of evidence-based medicine as well. Critical  
32 appraisal and assessing the quality of studies is a crucial component of evidence-based medicine. In  
33 2019, the Prediction model Risk Of Bias ASsessment Tool (PROBAST) was published [19, 20] to help a  
34 variety of stakeholders including, for example, systematic reviewers, researchers, journal editors,  
35 manuscript reviewers and policy makers involved in clinical guideline development, critically appraise  
36 the study design, conduct and analysis of prediction model studies. PROBAST comprises four domains  
37 (participants, predictors, outcome and analysis) and contains 20 signalling questions to facilitate risk  
38 of bias assessment. Clearly risk of bias assessment and reporting are intrinsically linked, in that judging  
39 risk of bias is predicated on what has been reported in the primary study. Whilst in principle PROBAST  
40 is relevant for prediction model studies using machine learning, different approaches to model  
41 development and validation, and terminology have appeared, and the ability to critically appraise  
42 these studies is crucial before they are implemented [21, 22]. Therefore, in parallel with the  
43 development of TRIPOD-AI, we will also develop PROBAST-AI, a tool to assess risk of bias in machine  
44 learning based multivariable prediction model studies.  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60



### Focus of TRIPOD-AI and PROBAST-AI

The focus of both TRIPOD-AI and PROBAST-AI is on reports of research or endeavours in which a multivariable prediction model is being developed (or updated), or validated (tested) using any machine learning technique. Conforming to the original TRIPOD and PROBAST publications, a multivariable prediction model is defined as any combination or equation of two or more predictors that is to be used for individualized predictions to estimate an individual's probability of having (diagnosis) or developing (prognosis) a particular health outcome or state. Predictors may have any form and emerge from patient history, physical examination, diagnostic, prognostic or monitoring tests and from undergone treatments. Outcomes may also have any form (dichotomous, categorical, continuous) and of any kind, such as, a particular condition or disorder being present or absent (diagnostic outcome or classification), short-term prognosis outcomes (e.g. hospital mortality, or postoperative complications), and long-term prognostic outcomes such as one year occurrence of treatment complications, five-year occurrence of metastases, or life-long survival).

As per the original publications, TRIPOD-AI and PROBAST-AI will also address prediction model studies from all medical care settings (public health, primary, secondary, tertiary and nursing home care) and all corresponding target populations (healthy individuals, suspected and diseased individuals).

TRIPOD-AI and PROBAST-AI are *not* meant to address:

- comparative studies that quantify the impact of using a prediction model as compared to not using the model [23];
- so-called predictor finding studies (also known as risk or prognostic factor studies) where multivariable machine learning techniques are used to identify (usually from a wider set of potential predictors) those predictors that are associated with an outcome, but not to develop a model that can be used for individualized predictions in new individuals;
- single medical test studies that use machine learning or AI techniques aimed to read, for example, CT or MRI, images to find which image-parameters are best associated with an outcome (such studies fall under the remit of STARD-AI [24]). If these image-parameters are included as predictors in a multivariable model combined with other predictors, TRIPOD-AI and PROBAST-AI may be useful.

### Methods/design

Both TRIPOD-AI and PROBAST-AI will be developed following published guidance from the EQUATOR Network [25]. We will develop the guideline in five stages: (i) systematic reviews to establish the

1  
2  
3 quality of current reporting, (ii) Delphi exercise, (iii) consensus meeting, (iv) development of the  
4 guidance statement, and (v) guideline dissemination. We have registered our intent to develop the  
5 TRIPOD extension for AI on the EQUATOR Network website ([www.equator-network.org](http://www.equator-network.org)), the TRIPOD  
6 website ([www.tripod-statement.org](http://www.tripod-statement.org)) and recently announced it in the Lancet [18], whilst the  
7 PROBAST-AI development has been announced on the PROBAST website ([www.probast.org](http://www.probast.org)).  
8  
9

### 13 **TRIPOD-AI/PROBAST-AI working group**

14 The TRIPOD/PROBAST Working Group will include: (1) an Executive Committee (2) an Advisory and  
15 Working Group; and (3) a large international Delphi Panel.  
16  
17

18  
19 The TRIPOD-AI/PROBAST-AI Executive Committee will be responsible for the leadership and  
20 coordination of all the processes involved in the development and dissemination of the TRIPOD-AI  
21 guideline. The Executive Committee consists of the two lead authors of the TRIPOD reporting guideline  
22 and the PROBAST tool, and also prediction model experts and researchers from the machine learning  
23 community. Key stakeholders for stage 2 (Delphi survey) will be identified and approached to  
24 participate and a subset of these key stakeholders (the Advisory Group) will participate in stage 3  
25 (consensus meeting).  
26  
27  
28  
29  
30  
31

32  
33 Here the term key stakeholder refers to a cross-sector participant (both industry and public sector)  
34 who falls into at least one of the following categories:  
35  
36

- 37  
38 1. researchers who have used machine learning in the context of clinical prediction, have clear  
39 knowledge and expertise in using machine learning or developed machine learning methods.  
40 These include applied (bio)medical investigators, statisticians, epidemiologists, and data  
41 scientists;  
42  
43
- 44  
45 2. assessors and approvers of artificial intelligence or machine learning model, such as regulatory  
46 assessors and ethics committee members;  
47  
48
- 49  
50 3. beneficiaries or users of the resultant TRIPOD-AI guidance and PROBAST-AI tool such as  
51 journal editors and journal reviewers;  
52  
53
- 54  
55 4. commissioners of research grants, such as funders;  
56  
57  
58  
59  
60

5. consumers of research results such as healthcare providers and patients and citizens.

### Stage 1 – Systematic review of current reporting

Two parallel systematic reviews are ongoing to evaluate the quality of current reporting in published studies developing, validating or updating machine learning based prediction models in the medical domain. Both systematic reviews will assess adherence of the reporting against the original TRIPOD Statement [1, 8], using the TRIPOD adherence checklist [26]. The reviews will also examine the methodological conduct of the primary studies, including a risk of bias assessment using the recently issued risk of bias tool (quality appraisal) for diagnostic and prognostic prediction model studies (PROBAST) [19, 20], and will draw out specific issues, currently not covered by TRIPOD and PROBAST relating to machine learning. The protocols for the two systematic reviews have been registered with the International Prospective Register of Systematic Reviews (PROSPERO IDs CRD42019140361 and CRD42019161764). One review (CRD42019161764) will examine the quality of reporting of machine learning based prediction model studies across all medical fields (between January 2018 to December 2019), whilst the other review (CRD42019140361) will focus on the quality of reporting of machine learning based prediction model studies published in oncology (between January 2019 to September 2019).

Undertaking these reviews serves two purposes: (1) to understand the completeness of current reporting of machine learning based prediction model studies in the medical literature, and (2) to identify unique reporting items for consideration for TRIPOD extension, and unique risk of bias or quality items for PROBAST extension. The data collection for this phase is underway. The reviews will evaluate the current completeness of reporting and the quality of the research and identify additional reporting and quality items to be considered for TRIPOD-AI and PROBAST-AI.

These two reviews will evaluate the current completeness of reporting and the quality of the research. Together with other evidence [3, 4, 16, 17, 27] from existing methodological guidance papers, they will provide important information on the transparency and quality of reporting. Using the original TRIPOD and PROBAST checklists as starting points, the Executive Committee will identify in the literature the preliminary items to consider in Stage 2 (the Delphi study) and therefore inclusion in the eventual TRIPOD-AI checklist and PROBAST-AI tool.

## **Stage 2 – Delphi exercise**

We will perform an extensive Delphi survey among a large international network of relevant stakeholders, with a maximum of three rounds, to help decide on items that could be modified, added to, or removed from the TRIPOD 2015 checklist to form the TRIPOD-AI checklist, and subsequently the PROBAST-AI checklist.

### ***Design***

The Delphi process will comprise of a series of rounds where panellists will independently and anonymously evaluate and achieve consensus on the inclusion or exclusion of the proposed reporting and quality items – in addition to suggesting additional items. The process will be repeated for a maximum of three rounds. Following each round, participants will be provided with structured feedback of the previous round to help reconcile individual opinions and achieve group consensus. Items achieving a high level of agreement ( $\geq 70\%$ ) will be taken forward to the consensus meeting (stage 3).

### ***Selection of potential items***

The list of items for TRIPOD-AI (and PROBAST-AI) will be collated by the Executive Committee, including the results of the two systematic reviews, any other available studies on methodology or reporting of machine learning based prediction models, and expert recommendations from the Delphi panellists. Relevant methodological guidance or methodological papers will be retrieved to identify additional candidate reporting and quality items for machine learning based prediction model studies. Pre-selection involves dividing items into those to further consider, those that can be provided as optional guidance (to be outlined in an Explanation and Elaboration accompanying document), or those not to consider for potential inclusion. Delphi participants will have the opportunity to view and provide feedback in each round, and also to suggest new items.

### ***Recruitment process and participants***

Delphi participants will be identified through professional networks of the Executive Committee, participation in the Delphi exercise of the original TRIPOD guideline (and TRIPOD for Abstracts and TRIPOD Cluster Delphi surveys), original PROBAST Delphi exercise, via self-response to the Lancet 2019 paper where TRIPOD-AI was announced [18], and responses to social media announcements of TRIPOD-AI (e.g., Twitter).

1  
2  
3 We will invite international participants with diverse roles (e.g., researchers, healthcare professionals,  
4 journal editors, funders, policy makers, healthcare regulators, end users of prediction models) from a  
5 range of settings (e.g., universities, hospitals, primary care, biomedical journals, non-profit  
6 organisations, and for-profit organisations). Participants will be invited via personalized email that will  
7 describe the TRIPOD-AI extension and PROBAST-AI tool development, and explain the objective,  
8 process, and timelines of the Delphi exercise. We plan to invite at least 100 participants to the Delphi  
9 survey. In all rounds, the survey will remain open for three weeks, with a reminder email sent one  
10 week after the initial invitation.  
11  
12  
13  
14  
15  
16  
17

18 Informed consent from participants will be obtained using an online consent form and participants  
19 can withdraw at any time. Individuals who indicate that they wish to opt out of the survey will be  
20 removed from subsequent invitations. Participants will not know the identities of other individuals in  
21 the Delphi panel, nor will they know the specific answers that any individual provides.  
22  
23  
24  
25  
26

### 27 **Participants**

28 Participants will not know the identities of other individuals in the Delphi panel, nor will they know  
29 the specific answers that any individual provides. In all rounds, the survey will remain open for three  
30 weeks, with a reminder email sent one week after the initial invitation. Individuals who indicate that  
31 they wish to opt out of the survey will be removed from subsequent invitations.  
32  
33  
34  
35  
36

### 37 **Procedure for selection of items**

38 We plan to ask participants to consider the following guiding principles when reviewing existing, new  
39 or modified items for inclusion: 1) reporting of the item should facilitate reproducibility of the study  
40 (i.e. users should be able to recreate the findings based on the information reported); 2) reporting of  
41 the item facilitates assessment of the quality and risk of bias in and applicability of the machine  
42 learning study findings, to enhance their uptake and use in subsequent studies, systematic reviews  
43 and daily practice; 3) item is likely relevant to nearly all prediction model studies; 4) the set of items  
44 represent the minimum that should be reported in all machine learning studies developing, validating  
45 or updating a diagnostic or prognostic prediction model.  
46  
47  
48  
49  
50  
51  
52

### 53 **Round 1**

54 Participants will be asked to rate on a 5-point Likert scale, the extent to which they agree with the  
55 inclusion of each checklist item in the TRIPOD-AI extension and PROBAST-AI tool (1=strongly disagree,  
56 2=somewhat disagree, 3=I don't know, 4=somewhat agree, 5=strongly agree). A free-text box will be  
57  
58  
59  
60

1  
2  
3 provided for general comments on each item (to justify their decision or suggest wording changes),  
4 and a free-text box will be provided at the end of the survey to suggest additional checklist items or  
5 provide general comments on the checklist. The survey will be pilot-tested for usability and clarity to  
6 a small number of individuals familiar with prediction models or machine learning but not involved in  
7 the TRIPOD-AI guideline extension or PROBAST-AI tool, and revised accordingly based on their  
8 feedback.  
9

### 15 **Round 2**

16 The same participants involved in round 1 will be invited to participate in round 2. Participants will be  
17 provided with their first-round responses on each item, an anonymised summary of the group ratings  
18 and anonymised comments to justify ratings. Using the same format as round 1, participants will be  
19 presented with each item, including any new items suggested during round 1, and again express the  
20 extent to which they agree with the inclusion of the item in the TRIPOD-AI checklist or PROBAST-AI  
21 tool, considering the structured feedback to inform their responses. Participants who were invited to  
22 participate in round 1, but who did not respond will be invited to participate in round 2, and will be  
23 presented with an anonymised summary of the group ratings. Items that reached a high-level of  
24 agreement (scoring 4 or 5) in round 1 ( $\geq 70\%$ ) will be presented for information purposes only, with  
25 no voting on these items, though a free-text box will be provided for any comments. A third Delphi  
26 round will be used if deemed necessary by the Executive Committee.  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36

### 37 **Results from the Delphi survey**

38 Item scores will be summarised for the entire panel as a whole, as appropriate (e.g., frequency and  
39 proportions across the rating categories) accompanied by a narrative summary of findings, comments,  
40 and suggestions. Results from both rounds of the survey will be discussed by the Executive Committee.  
41 For items where there was no consensus following the second Delphi round will be discussed by the  
42 Executive Committee, and will be considered for discussion at the subsequent consensus meeting.  
43  
44  
45  
46  
47

### 48 **Stage 3 – Consensus meeting**

49 Two virtual consensus meetings (separately for TRIPOD-AI and PROBAST-AI), both spread over 2 days,  
50 will be held with the objective of discussing the results from the Delphi exercise and finalising items  
51 to be included in the reporting guideline and risk of bias tool. The composition of the consensus group  
52 will reflect the diversity of the key stakeholders addressed above. Key experts participating in the  
53 Delphi exercise will be considered to participate in the consensus meeting. We will also consider  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 inviting experts who did not contribute to the Delphi to participate in the consensus. A total of around  
4  
5 25-30 international participants are expected to contribute to the virtual consensus meeting.  
6  
7

### 8 **Procedure**

9  
10 The agenda and any material (e.g., results from the systematic reviews and Delphi) for the consensus  
11 meeting will be prepared by the Executive Committee and will be shared with attendees in advance.  
12  
13 Members of the Executive Committee will facilitate a structured discussion on the rationale behind  
14 each item identified in the Delphi exercise. Consensus meeting participants will then be given the  
15 opportunity to discuss each item (reporting item for TRIPOD-AI and signalling question for PROBAST-  
16 AI), and vote on each item. The decision to retain an item in the TRIPOD-AI and PROBAST-AI will be  
17 based on achieving at least 70% support from the consensus meeting participants. The group will  
18 agree on the draft list of reporting items for the final TRIPOD-AI extension and PROBAST-AI tool.  
19  
20 Specific item wording will not be discussed during the meeting, though participants can suggest and  
21 the group to agree on general intent and meaning of the item. Plans for dissemination will be  
22 discussed at the end of the consensus meeting.  
23  
24  
25  
26  
27  
28  
29

### 30 **Pilot testing**

31 We will invite authors of machine learning prediction model studies in the medical domain, doctoral  
32 students undertaking prediction model, machine learning courses or workshops, and peer reviewers  
33 and editors of journals who frequently publish such prediction model studies, to pilot the use of a  
34 draft version of the TRIPOD-AI checklist and PROBAST-AI tool. We will ask those who pilot the checklist  
35 and tool whether the wording of items is ambiguous or difficult to interpret.  
36  
37  
38  
39  
40  
41

### 42 **Stage 4 – Development of the draft TRIPOD-AI statement, PROBAST-AI and Explanation &** 43 **Elaboration documents**

44  
45 The Executive Committee will lead the development of the TRIPOD-AI reporting guidance and  
46 PROBAST-AI signalling questions based on the agreed list of items from the consensus meeting (stage  
47 3). The Executive Committee will invite a subset of members from the consensus meeting (to form a  
48 writing group) to help draft the Explanation & Elaboration paper.  
49  
50  
51

52  
53  
54  
55 The Executive Committee will reserve the right to update (that is remove or add) additional items to  
56 the TRIPOD-AI checklist during the development of the TRIPOD-AI statement, if and as necessary (as  
57 a result of the pilot testing).  
58  
59  
60

1  
2  
3  
4  
5 For each of the TRIPOD-AI extension and the PROBAST-AI risk of bias tool, two manuscripts will be  
6 developed; (1) the Statement paper, presenting the checklist/tool and describing the process of how  
7 it was developed and (2) an Explanation & Elaboration paper. The Explanation & Elaboration papers  
8 will outline the rationale of the reporting items (TRIPOD-AI) and signalling questions (PROBAST-AI),  
9 examples of good reporting (TRIPOD-AI) and examples of how to use PROBAST-AI. Drafts of the papers  
10 will be circulated to all participants of the consensus meeting for their comments.  
11  
12  
13  
14  
15

### 16 **Stage 5 – Guideline dissemination**

17  
18 The dissemination strategy will be informed by discussions at the consensus meeting. We will aim to  
19 seek simultaneous publication in key journals to target different readerships. To increase visibility and  
20 aid uptake, the TRIPOD-AI checklist and PROBAST-AI tool will be published open access, and made  
21 available on the TRIPOD website along with other TRIPOD extensions ([www.tripod-statement.org](http://www.tripod-statement.org)),  
22 and on the PROBAST website ([www.probast.org](http://www.probast.org)) respectively, as well on the PROGRESS website  
23 ([www.prognosisresearch.com](http://www.prognosisresearch.com)). The TRIPOD-AI extension will be indexed on the EQUATOR website  
24 ([www.equator-network.org](http://www.equator-network.org)). Social media will be used to help disseminate the extension. The  
25 Executive Committee will (and consensus participants will be encouraged to) publicise the TRIPOD-AI  
26 statement and PROBAST-AI tool at key conferences and courses.  
27  
28  
29  
30  
31  
32  
33  
34

### 35 **Publication plan**

36 It is envisaged that the following publications will arise from the TRIPOD-AI and PROBAST-AI initiative:

- 37 • Publication 1: Study protocol
  - 38 • Publication 2: Systematic review protocol (with registration on PROSPERO)
  - 39 • Publication 3 & 4: Systematic reviews
  - 40 • Publication 5 & 6: TRIPOD-AI statement and the Explanation and Elaboration paper
  - 41 • Publication 7 & 8: PROBAST-AI tool and the Explanation and Elaboration paper
- 42  
43  
44  
45  
46  
47  
48

### 49 **Conclusion**

50 The number of prediction model studies using machine learning methods is rapidly increasing,  
51 including developed, validated or updated prediction models. Ensuring that key details are reported  
52 is important so that readers can evaluate the study quality, and interpret its findings including the  
53 developed, validated or updated prediction model to enhance their uptake in subsequent research  
54 (e.g. validation studies), evidence synthesis projects (e.g. systematic reviews of prediction models),  
55 and in daily practice by healthcare professionals, patients or citizens. We anticipate that TRIPOD-AI  
56  
57  
58  
59  
60



1  
2  
3 will help authors transparently report their study and help reviewers, editors, policy makers and end-  
4 users understand the methods and findings, and thereby reduce research waste. Similarly, we  
5 anticipate PROBAST-AI will help researchers, clinicians, systematic reviewers and policy-makers  
6 critically appraise the design, conduct and analysis of machine learning based prediction model  
7 studies.  
8  
9  
10  
11  
12

### 13 **Patient and Public Involvement**

14 No patients or members of the public were involved in the development of this protocol. Patient and  
15 public involvement is planned for the virtual consensus meeting.  
16  
17  
18

### 19 **Ethics**

20 Ethical approval has been granted by the Central University Research Ethics Committee (CUREC),  
21 University of Oxford on 10-December-2020 (R73034/RE001).  
22  
23  
24  
25

### 26 **Contributor statement**

27 Gary S. Collins, Paula Dhiman, Constanza L. Andaur Navarro, Jie Ma, Lotty Hooft, Johannes B. Reitsma,  
28 Patricia Logullo, Andrew L. Beam, Lily Peng, Ben Van Calster, Maarten van Smeden, Richard D. Riley,  
29 Karel G.M. Moons were involved in the planning and design of the study. Gary Collins drafted the  
30 manuscript with all authors contributing to the writing.  
31  
32  
33  
34  
35

### 36 **Competing interests**

37 The authors declare no competing interests.  
38  
39  
40

### 41 **Data sharing statement**

42 There is no data to share.  
43  
44  
45

### 46 **Funding**

47 This research was supported by Health Data Research UK, an initiative funded by UKResearch and  
48 Innovation, Department of Health and Social Care (England) and the devolved administrations, and  
49 leading medical research charities, Cancer Research UK programme grant (C49297/A27294), the NIHR  
50 Biomedical Research Centre, Oxford, and the Netherlands Organisation for Scientific Research. The  
51 funders have no role in the development of this protocol and will not have a role in the data collection,  
52 analyses, interpretation of the data, and publication of the findings.  
53  
54  
55  
56  
57  
58  
59

### 60 **References**

1. Collins GS, Reitsma JB, Altman DG, Moons KGM. Transparent Reporting of a multivariable prediction model for Individual Prognosis Or Diagnosis (TRIPOD): The TRIPOD Statement. *Ann Intern Med.* 2015;162:55–63.
2. Moons KG, Kengne AP, Woodward M, Royston P, Vergouwe Y, Altman DG, et al. Risk prediction models: I. Development, internal validation, and assessing the incremental value of a new (bio)marker. *Heart.* 2012;98:683–90.
3. Collins GS, Mallett S, Omar O, Yu LM. Developing risk prediction models for type 2 diabetes: a systematic review of methodology and reporting. *BMC Med.* 2011;9:103.
4. Collins GS, de Groot JA, Dutton S, Omar O, Shanyinde M, Tajar A, et al. External validation of multivariable prediction models: a systematic review of methodological conduct and reporting. *BMC Med Res Meth.* 2014;14:40.
5. Bouwmeester W, Zuithoff NP, Mallett S, Geerlings MI, Vergouwe Y, Steyerberg EW, et al. Reporting and methods in clinical prediction research: a systematic review. *PLoS Med.* 2012;9:e1001221.
6. Mallett S, Royston P, Dutton S, Waters R, Altman DG. Reporting methods in studies developing prognostic models in cancer: a review. *BMC Med.* 2010;8:20.
7. Chalmers I, Glasziou P. Avoidable waste in the production and reporting of research evidence. *Lancet.* 2009;374:86–9.
8. Moons KGM, Altman DG, Reitsma JB, Ioannidis JPA, Macaskill P, Steyerberg EW, et al. Transparent Reporting of a multivariable prediction model for Individual Prognosis Or Diagnosis (TRIPOD): Explanation and Elaboration. *Ann Intern Med.* 2015;162:W1–73.
9. Yu KH, Beam AL, Kohane IS. Artificial intelligence in healthcare. *Nat Biomed Eng.* 2018;2:719–31.
10. Beam AL, Kohane IS. Big Data and Machine Learning in Health Care. *JAMA.* 2018.
11. Ghassemi M, Naumann T, Schulam P, Beam AL, Chen IY, Ranganath R. Practical guidance on artificial intelligence for health-care data. *Lancet Digit Health.* 2019;1:e157–9.
12. Beam AL, Manrai AK, Ghassemi M. Challenges to the Reproducibility of Machine Learning Models in Health Care. *JAMA.* 2020. doi:10.1001/jama.2019.20866.
13. Sendak M, D’Arcy J, Kashyap S, Gao M, Nichols M, Corey K, et al. A Path for Translation of Machine Learning Products into Healthcare Delivery. *EMJ Innov.* 2020. doi:10.33590/emjinnov/19-00172.
14. Wiens J, Saria S, Sendak M, Ghassemi M, Liu VX, Doshi-Velez F, et al. Do no harm: a roadmap for responsible machine learning for health care. *Nat Med.* 2019. doi:10.1038/s41591-019-0548-6.
15. Wynants L, Van Calster B, Collins GS, Riley RD, Heinze G, Schuit E, et al. Prediction models for diagnosis and prognosis of covid-19: systematic review and critical appraisal. *BMJ.* 2020;369:m1328.
16. Shillan D, Sterne JAC, Champneys A, Gibbison B. Use of machine learning to analyse routinely collected intensive care unit data: a systematic review. *Crit Care.* 2019;23:284.
17. Christodoulou E, Ma J, Collins GS, Steyerberg EW, Verbakel JY, van Calster B. A systematic review shows no performance benefit of machine learning over logistic regression for clinical prediction models. *J Clin Epidemiol.* 2019.
18. Collins GS, Moons KGM. Reporting of artificial intelligence prediction models. *The Lancet.* 2019;393:1577–9.

19. Wolff RF, Moons KGM, Riley RD, Whiting PF, Westwood M, Collins GS, et al. PROBAST: A Tool to Assess the Risk of Bias and Applicability of Prediction Model Studies. *Ann Intern Med*. 2019;170:51–8.
20. Moons KGM, Wolff RF, Riley RD, Whiting PF, Westwood M, Collins GS, et al. PROBAST: A Tool to Assess Risk of Bias and Applicability of Prediction Model Studies: Explanation and Elaboration. *Ann Intern Med*. 2019;170:W1–33.
21. Liu Y, Chen P-HC, Krause J, Peng L. How to Read Articles That Use Machine Learning: Users' Guides to the Medical Literature. *JAMA*. 2019;322:1806.
22. Faes L, Liu X, Wagner SK, Fu DJ, Balaskas K, Sim DA, et al. A Clinician's Guide to Artificial Intelligence: How to Critically Appraise Machine Learning Studies. *Transl Vis Sci Technol*. 2020;9:7.
23. Moons KGM, Altman DG, Vergouwe Y, Royston P. Prognosis and prognostic research: application and impact of prognostic models in clinical practice. *BMJ*. 2009;338:b606.
24. Sounderajah V, Ashrafian H, Aggarwal R, De Fauw J, Denniston AK, Greaves F, et al. Developing specific reporting guidelines for diagnostic accuracy studies assessing AI interventions: The STARD-AI Steering Group. *Nat Med*. 2020. doi:10.1038/s41591-020-0941-1.
25. Moher D, Schulz KF, Simera I, Altman DG. Guidance of developers of health research reporting guidelines. *PLoS Med*. 2010;7:e1000217.
26. Heus P, Damen JAAG, Pajouheshnia R, Scholten RJPM, Reitsma JB, Collins GS, et al. Poor reporting of multivariable prediction model studies: towards a targeted implementation strategy of the TRIPOD statement. *BMC Med*. 2018;16.
27. Liu X, Faes L, Kale AU, Wagner SK, Fu DJ, Bruynseels A, et al. A comparison of deep learning performance against health-care professionals in detecting diseases from medical imaging: a systematic review and meta-analysis. *Lancet Digit Health*. 2019;1:e271–97.
28. Moons KG, Hooft L, Williams K, Hayden JA, Damen JA, Riley RD. Implementing systematic reviews of prognosis studies in Cochrane. *Cochrane Database Syst Rev*. 2018. doi:10.1002/14651858.ED000129.

# BMJ Open

## A protocol for development of a reporting guideline (TRIPOD-AI) and risk of bias tool (PROBAST-AI) for diagnostic and prognostic prediction studies based on artificial intelligence

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2020-048008.R1
Article Type:	Protocol
Date Submitted by the Author:	14-Apr-2021
Complete List of Authors:	Collins, Gary; Oxford University, Centre for Statistics in Medicine Dhiman, Paula; Oxford University, Nuffield Department of Orthopaedics, Rheumatology & Musculoskeletal Sciences Andaur Navarro, Constanza L.; Julius Center for Health Sciences and Primary Care, Epidemiology Ma, Ji; University of Oxford Hooft, Lotty; Julius Center for Health Sciences and Primary Care, Cochrane Netherlands Reitsma, Johannes; Julius Center for Health Sciences and Primary Care Logullo, Patricia; University of Oxford Beam, Andrew; Harvard Medical School, Peng, Lily; Google Inc Van Calster, Ben; KU Leuven, Department of Development and Regeneration van Smeden, Maarten; Universiteit Leiden, Riley, Richard; Keele University Moons, Karel; Julius Center for Health Sciences and Primary Care, Epidemiology
<b>Primary Subject Heading</b>:	Medical publishing and peer review
Secondary Subject Heading:	Epidemiology
Keywords:	STATISTICS & RESEARCH METHODS, EPIDEMIOLOGY, GENERAL MEDICINE (see Internal Medicine)

SCHOLARONE™  
Manuscripts



I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our [licence](#).

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which [Creative Commons](#) licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

# A protocol for development of a reporting guideline (TRIPOD-AI) and risk of bias tool (PROBAST-AI) for diagnostic and prognostic prediction studies based on artificial intelligence

Gary S. Collins<sup>1,2\*</sup>, Paula Dhiman<sup>1,2</sup>, Constanza L. Andaur Navarro<sup>3,4</sup>, Jie Ma<sup>1</sup>, Lotty Hooft<sup>3,4</sup>, Johannes B. Reitsma<sup>3</sup>, Patricia Logullo<sup>1</sup>, Andrew L. Beam<sup>5,6</sup>, Lily Peng<sup>7</sup>, Ben Van Calster<sup>8,9,10</sup>, Maarten van Smeden<sup>3</sup>, Richard D. Riley<sup>11</sup>, Karel G.M. Moons<sup>3,4\*</sup>

<sup>1</sup> Centre for Statistics in Medicine, Nuffield Department of Orthopaedics, Rheumatology & Musculoskeletal Sciences, University of Oxford, Oxford, OX3 7LD, United Kingdom

<sup>2</sup> NIHR Oxford Biomedical Research Centre, John Radcliffe Hospital, Oxford, United Kingdom NIHR Oxford Biomedical Research Centre, John Radcliffe Hospital, Oxford, United Kingdom

<sup>3</sup> Julius Center for Health Sciences & Primary Care, and Cochrane Netherlands, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands

<sup>4</sup> Cochrane Netherlands, University Medical Center Utrecht, Utrecht University, The Netherlands

<sup>5</sup> Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, Massachusetts, United States

<sup>6</sup> Department of Biomedical Informatics, Harvard Medical School, Boston, Massachusetts, United States

<sup>7</sup> Google Health, 3400 Hillview Ave, Palo Alto, CA 94304, United States

<sup>8</sup> KU Leuven, Department of Development and Regeneration, Leuven, Belgium

<sup>9</sup> Department of Biomedical Data Sciences, Leiden University Medical Centre (LUMC), Leiden, the Netherlands

<sup>10</sup> EPI-centre, KU Leuven, Leuven, Belgium

<sup>11</sup> Centre for Prognosis Research, School of Medicine, Keele University, Staffordshire, ST5 5BG, United Kingdom.

\* Both authors contributed equally

Address for correspondence:

Professor Gary S Collins

Centre for Statistics in Medicine

Nuffield Department of Orthopaedics, Rheumatology & Musculoskeletal Sciences

University of Oxford

Oxford, OX3 7LD

United Kingdom.

Email: [gary.collins@csm.ox.ac.uk](mailto:gary.collins@csm.ox.ac.uk)

Twitter: @GSCollins, @CarlMoons

ORCID: [0000-0002-2772-2316](https://orcid.org/0000-0002-2772-2316)

## Abstract

**Introduction:** The Transparent Reporting of a multivariable prediction model of Individual Prognosis Or Diagnosis (TRIPOD) statement and the Prediction model Risk Of Bias ASsessment Tool (PROBAST) were both published to improve the reporting and critical appraisal of prediction model studies for diagnosis and prognosis. This paper describes the processes and methods that will be used to develop an extension to the TRIPOD statement (TRIPOD-AI) and the PROBAST (PROBAST-AI) tool for prediction model studies that applied machine learning techniques.

**Methods and Analysis:** TRIPOD-AI and PROBAST-AI will be developed following published guidance from the EQUATOR Network, and will comprise five stages. Stage one will comprise two systematic reviews (across all medical fields and specifically in oncology) to examine the quality of reporting in published machine-learning based prediction model studies. In stage two we will consult a diverse group of key stakeholders using a Delphi process to identify items to be considered for inclusion in TRIPOD-AI and PROBAST-AI. Stage three will be a virtual consensus meeting to consolidate and prioritise key items to be included in TRIPOD-AI and PROBAST-AI. Stage four will involve developing the TRIPOD-AI checklist and the PROBAST-AI tool, and writing the accompanying explanation and elaboration papers. In the final stage, stage 5, we will disseminate TRIPOD-AI and PROBAST-AI via journals, conferences, blogs, websites (including TRIPOD, PROBAST and EQUATOR Network), and social media. TRIPOD-AI will provide researchers working on prediction model studies based on machine-learning with a reporting guideline that can help them report key details that readers need to evaluate the study quality and interpret its findings, potentially reducing research waste. We anticipate PROBAST-AI will help researchers, clinicians, systematic reviewers and policymakers critically appraise the design, conduct and analysis of machine learning based prediction model studies, with a robust standardised tool for bias evaluation.

## Ethics and Dissemination

Ethical approval has been granted by the Central University Research Ethics Committee (CUREC), University of Oxford on 10-December-2020 (R73034/RE001). Findings from this study will be disseminated through peer review publications.

**Keywords:** prediction, artificial intelligence, machine learning, reporting guideline, risk of bias, TRIPOD, PROBAST

## Article Summary

### Strengths and limitations of this study

- The reporting of clinical prediction models using artificial intelligence is poor.
- There are no guidelines for the reporting or risk of bias assessment of clinical prediction models using artificial intelligence.
- The strengths of this study is that it follows published guidance from the EQUATOR Network for developing reporting guidelines.
- Expert opinion and consensus will be obtained from multiple stakeholders (statisticians, clinician scientists, epidemiologists, computer scientists, funders, healthcare policy makers, patients, and industry leaders).



## Background

Models that predict clinical outcomes are abundant in the medical literature and are broadly categorised as those that estimate the probability of the presence of a particular outcome (diagnostic) or whether a particular outcome (e.g. event) will occur in the future (prognostic) [1]. Traditionally these models (herein referred to as prediction model) have been developed using regression-based methods, typically logistic regression for short-term outcomes and Cox regression for longer-term outcomes [2]. Numerous reviews have observed that studies describing the development and validation (including updating) of a prediction model often fail to report key information to help readers judge the methods and have a complete, transparent and clear picture of the model's predictive accuracy and other relevant details such as the target population and the content of the model itself [3–6]. The absence of full and comprehensive reporting limits the usability of the findings of these studies, e.g., in subsequent validation studies, evidence synthesis studies, or in daily practice, and therefore contribute to research waste [7]. In response to this, in 2015, the Transparent Reporting of a multivariable prediction model for Individual Prognosis Or Diagnosis (TRIPOD) Statement was published [1, 8]. The TRIPOD Statement is a checklist of 22-items that authors should report with sufficient detail and clarity to inform how the study was carried out.

Since the publication of the TRIPOD Statement, artificial intelligence (AI) and in particular machine learning, approaches to clinical prediction have evolved and grown in popularity with the number of AI and machine learning publications rapidly rising [9–14]. This is evident within a recent review of COVID-19 related prediction models, where 57 (out of 107 included studies) used machine learning methods to develop their model [15].

Machine learning, a branch of artificial intelligence, can be broadly described as data analytical methods that learn from data without being explicitly programmed, with patterns identified based on the data itself. They are often described as having flexibility to capture complex associations particularly in large and unstructured data and complexity in modelling. Whilst the vast majority of the items in the TRIPOD Statement are relevant to machine learning based prediction model studies, there are some unique challenges with machine learning that are not captured. Due to their complexity, these prediction models are typically considered to be 'black box', unlike say regression-based models where the full model can be transparently presented (e.g., as an equation containing all the regression coefficients). Also, whilst many machine learning methods have origins in the statistical literature, two (overlapping) prediction model cultures have emerged as those from a statistical/epidemiological background and those from the computer science/data sciences [16].

1  
2  
3 Although there is clear overlap, different approaches to model development, validation and updating  
4 have appeared, and different and sometimes conflicting terminology have arisen.  
5  
6  
7

8 Due to the relative novelty of applying machine learning methods to clinical prediction modelling,  
9 there is little information on the quality of reporting of these studies. However, the few reviews that  
10 have examined the completeness of reporting of have concluded that reporting is poor [17, 18]. In  
11 response to these concerns, guidance is required to help authors fully describe their prediction model  
12 study when machine learning methods were used. Therefore the TRIPOD group initiated a large  
13 international project to develop a consensus based extension of TRIPOD with specific focus on  
14 reporting of studies that undertake the development, validation or updating of a diagnostic or  
15 prognostic prediction model, using machine learning techniques – herein referred to as TRIPOD-AI  
16 [19]. The TRIPOD-AI extension, comprising a checklist and an accompanying elaboration and  
17 explanation document will provide researchers, authors, reviewers, editors, users, and other  
18 stakeholders of machine learning based prediction model studies, with guidance on the minimal set  
19 of items to report, with detailed examples of good reporting for each item.  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29

30 Complete reporting allows studies to be understood, replicated and used. However, critical appraisal  
31 and of the quality of study method is a crucial component of evidence-based medicine as well. Critical  
32 appraisal and assessing the quality of studies is a crucial component of evidence-based medicine. In  
33 2019, the Prediction model Risk Of Bias ASsessment Tool (PROBAST) was published [20, 21] to help a  
34 variety of stakeholders including, for example, systematic reviewers, researchers, journal editors,  
35 manuscript reviewers and policy makers involved in clinical guideline development, critically appraise  
36 the study design, conduct and analysis of prediction model studies. PROBAST comprises four domains  
37 (participants, predictors, outcome and analysis) and contains 20 signalling questions to facilitate risk  
38 of bias assessment. Clearly risk of bias assessment and reporting are intrinsically linked, in that judging  
39 risk of bias is predicated on what has been reported in the primary study. Whilst in principle PROBAST  
40 is relevant for prediction model studies using machine learning, different approaches to model  
41 development and validation, and terminology have appeared, and the ability to critically appraise  
42 these studies is crucial before they are implemented [22, 23]. Therefore, in parallel with the  
43 development of TRIPOD-AI, we will also develop PROBAST-AI, a tool to assess risk of bias in machine  
44 learning based multivariable prediction model studies.  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

### Focus of TRIPOD-AI and PROBAST-AI

The focus of both TRIPOD-AI and PROBAST-AI is on reports of research or endeavours in which a multivariable prediction model is being developed (or updated), or validated (tested) using any (supervised) machine learning technique. Conforming to the original TRIPOD and PROBAST publications, a multivariable prediction model is defined as any combination or equation of two or more predictors that is to be used for individualized predictions to estimate an individual's probability of having (diagnosis) or developing (prognosis) a particular health outcome or state. Predictors may have any form and emerge from patient history, physical examination, diagnostic, prognostic or monitoring tests and from undergone treatments. Outcomes may also have any form (dichotomous, categorical, continuous) and of any kind, such as, a particular condition or disorder being present or absent (diagnostic outcome or classification), short-term prognosis outcomes (e.g., hospital mortality, or postoperative complications), and long-term prognostic outcomes such as one year occurrence of treatment complications, five-year occurrence of metastases, or life-long survival).

As per the original publications, TRIPOD-AI and PROBAST-AI will also address prediction model studies from all medical care settings (public health, primary, secondary, tertiary and nursing home care) and all corresponding target populations (healthy individuals, suspected and diseased individuals).

TRIPOD-AI and PROBAST-AI are *not* meant to address:

- comparative studies that quantify the impact of using a prediction model as compared to not using the model [24];
- so-called predictor finding studies (also known as risk or prognostic factor studies) where multivariable machine learning techniques are used to identify (usually from a wider set of potential predictors) those predictors that are associated with an outcome, but not to develop a model that can be used for individualized predictions in new individuals;
- single medical test studies that use machine learning or AI techniques aimed to read, for example, CT or MRI, images to find which image-parameters are best associated with an outcome (such studies fall under the remit of STARD-AI [25]). If these image-parameters are included as predictors in a multivariable model combined with other predictors, TRIPOD-AI and PROBAST-AI may be useful.

### Methods/design

Both TRIPOD-AI and PROBAST-AI will be developed following published guidance from the EQUATOR Network [26]. We will develop the guideline in five stages: (i) systematic reviews to establish the

1  
2  
3 quality of current reporting, (ii) Delphi exercise, (iii) consensus meeting, (iv) development of the  
4 guidance statement, and (v) guideline dissemination. We have registered our intent to develop the  
5 TRIPOD extension for AI on the EQUATOR Network website ([www.equator-network.org](http://www.equator-network.org)), the TRIPOD  
6 website ([www.tripod-statement.org](http://www.tripod-statement.org)) and recently announced it in the Lancet [19], whilst the  
7 PROBAST-AI development has been announced on the PROBAST website ([www.probast.org](http://www.probast.org)).  
8  
9

### 13 **TRIPOD-AI/PROBAST-AI working group**

14 The TRIPOD/PROBAST Working Group will include: (1) an Executive Committee (2) an Advisory and  
15 Working Group; and (3) a large international Delphi Panel.  
16  
17

18  
19 The TRIPOD-AI/PROBAST-AI Executive Committee will be responsible for the leadership and  
20 coordination of all the processes involved in the development and dissemination of the TRIPOD-AI  
21 guideline. The Executive Committee consists of the two lead authors of the TRIPOD reporting guideline  
22 and the PROBAST tool, and also prediction model experts and researchers from the machine learning  
23 community. Key stakeholders for stage 2 (Delphi survey) will be identified and approached to  
24 participate and a subset of these key stakeholders (the Advisory Group) will participate in stage 3  
25 (consensus meeting).  
26  
27  
28  
29  
30  
31

32  
33 Here the term key stakeholder refers to a cross-sector participant (both industry and public sector)  
34 who falls into at least one of the following categories:  
35  
36

- 37  
38 1. researchers who have used machine learning in the context of clinical prediction, have clear  
39 knowledge and expertise in using machine learning or developed machine learning methods.  
40 These include applied (bio)medical investigators, statisticians, epidemiologists, and data  
41 scientists;  
42  
43
- 44 2. assessors and approvers of artificial intelligence or machine learning model, such as regulatory  
45 assessors and ethics committee members;  
46  
47
- 48 3. beneficiaries or users of the resultant TRIPOD-AI guidance and PROBAST-AI tool such as  
49 journal editors and journal reviewers;  
50  
51
- 52 4. commissioners of research grants, such as funders;  
53  
54  
55  
56  
57  
58  
59  
60

5. consumers of research results such as healthcare providers and patients and citizens.

### Stage 1 – Systematic review of current reporting

Two parallel systematic reviews are ongoing to evaluate the quality of current reporting in published studies developing, validating or updating machine learning based prediction models in the medical domain. Both systematic reviews will assess adherence of the reporting against the original TRIPOD Statement [1, 8], using the TRIPOD adherence checklist [27]. The reviews will also examine the methodological conduct of the primary studies, including a risk of bias assessment using the recently issued risk of bias tool (quality appraisal) for diagnostic and prognostic prediction model studies (PROBAST) [20, 21], and will draw out specific issues, currently not covered by TRIPOD and PROBAST relating to machine learning. The protocols for the two systematic reviews have been registered with the International Prospective Register of Systematic Reviews (PROSPERO IDs CRD42019140361 and CRD42019161764). One review (CRD42019161764) will examine the quality of reporting of machine learning based prediction model studies across all medical fields (between January 2018 to December 2019), whilst the other review (CRD42019140361) will focus on the quality of reporting of machine learning based prediction model studies published in oncology (between January 2019 to September 2019).

Undertaking these reviews serves two purposes: (1) to understand the completeness of current reporting of machine learning based prediction model studies in the medical literature, and (2) to identify unique reporting items for consideration for TRIPOD extension, and unique risk of bias or quality items for PROBAST extension. The data collection for this phase is underway. The reviews will evaluate the current completeness of reporting and the quality of the research and identify additional reporting and quality items to be considered for TRIPOD-AI and PROBAST-AI.

These two reviews will evaluate the current completeness of reporting and the quality of the research. Together with other evidence [3, 4, 17, 18, 28] from existing methodological guidance papers, they will provide important information on the transparency and quality of reporting. Using the original TRIPOD and PROBAST checklists as starting points, the Executive Committee will identify in the literature the preliminary items to consider in Stage 2 (the Delphi study) and therefore inclusion in the eventual TRIPOD-AI checklist and PROBAST-AI tool.

## **Stage 2 – Delphi exercise**

We will perform an extensive Delphi survey among a large international network of relevant stakeholders, with a maximum of three rounds, to help decide on items that could be modified, added to, or removed from the TRIPOD 2015 checklist to form the TRIPOD-AI checklist, and subsequently the PROBAST-AI checklist.

### ***Design***

The Delphi process will comprise of a series of rounds where panellists will independently and anonymously evaluate and achieve consensus on the inclusion or exclusion of the proposed reporting and quality items – in addition to suggesting additional items. The process will be repeated for a maximum of three rounds. Following each round, participants will be provided with structured feedback of the previous round to help reconcile individual opinions and achieve group consensus. Items achieving a high level of agreement ( $\geq 70\%$ ) will be taken forward to the consensus meeting (stage 3).

### ***Selection of potential items***

The list of items for TRIPOD-AI (and PROBAST-AI) will be collated by the Executive Committee, including the results of the two systematic reviews, any other available studies on methodology or reporting of machine learning based prediction models, and expert recommendations from the Delphi panellists. Relevant methodological guidance or methodological papers will be retrieved to identify additional candidate reporting and quality items for machine learning based prediction model studies. Pre-selection involves dividing items into those to further consider, those that can be provided as optional guidance (to be outlined in an Explanation and Elaboration accompanying document), or those not to consider for potential inclusion. Delphi participants will have the opportunity to view and provide feedback in each round, and also to suggest new items.

### ***Recruitment process and participants***

Delphi participants will be identified through professional networks of the Executive Committee, participation in the Delphi exercise of the original TRIPOD guideline (and TRIPOD for Abstracts and TRIPOD Cluster Delphi surveys), original PROBAST Delphi exercise, via self-response to the Lancet 2019 paper where TRIPOD-AI was announced [19], and responses to social media announcements of TRIPOD-AI (e.g., Twitter).

1  
2  
3 We will invite international participants with diverse roles (e.g., researchers, healthcare professionals,  
4 journal editors, funders, policy makers, healthcare regulators, end users of prediction models) from a  
5 range of settings (e.g., universities, hospitals, primary care, biomedical journals, non-profit  
6 organisations, and for-profit organisations). Participants will be invited via personalized email that will  
7 describe the TRIPOD-AI extension and PROBAST-AI tool development, and explain the objective,  
8 process, and timelines of the Delphi exercise. We plan to invite at least 200 participants to the Delphi  
9 survey. In all rounds, the survey will remain open for three weeks, with a reminder email sent one  
10 week after the initial invitation. In round two of the Delphi exercise, additional participants may be  
11 sought to ensure fair representation of all key stakeholders [29].  
12  
13  
14  
15  
16  
17  
18  
19

20 Informed consent from participants will be obtained using an online consent form and participants  
21 can withdraw at any time. Individuals who indicate that they wish to opt out of the survey will be  
22 removed from subsequent invitations. Participants will not know the identities of other individuals in  
23 the Delphi panel, nor will they know the specific answers that any individual provides.  
24  
25  
26  
27

### 28 ***Procedure for selection of items***

29 We plan to ask participants to consider the following guiding principles when reviewing existing, new  
30 or modified items for inclusion: 1) reporting of the item should facilitate reproducibility of the study  
31 (i.e. users should be able to recreate the findings based on the information reported); 2) reporting of  
32 the item facilitates assessment of the quality and risk of bias in and applicability of the machine  
33 learning study findings, to enhance their uptake and use in subsequent studies, systematic reviews  
34 and daily practice; 3) item is likely relevant to nearly all prediction model studies; 4) the set of items  
35 represent the minimum that should be reported in all machine learning studies developing, validating  
36 or updating a diagnostic or prognostic prediction model.  
37  
38  
39  
40  
41  
42  
43  
44

### 45 ***Round 1***

46 Participants will be asked to rate on a 5-point Likert scale, the extent to which they agree with the  
47 inclusion of each checklist item in the TRIPOD-AI extension and PROBAST-AI tool (1=strongly disagree,  
48 2=somewhat disagree, 3=I don't know, 4=somewhat agree, 5=strongly agree). A free-text box will be  
49 provided for general comments on each item (to justify their decision or suggest wording changes),  
50 and a free-text box will be provided at the end of the survey to suggest additional checklist items or  
51 provide general comments on the checklist. The survey will be pilot-tested for usability and clarity to  
52 a small number of individuals familiar with prediction models or machine learning but not involved in  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 the TRIPOD-AI guideline extension or PROBAST-AI tool, and revised accordingly based on their  
4 feedback.  
5  
6  
7

### 8 **Round 2**

9  
10 The same participants involved in round 1 will be invited to participate in round 2. Participants will be  
11 provided with their first-round responses on each item, an anonymised summary of the group ratings  
12 and anonymised comments to justify ratings. Using the same format as round 1, participants will be  
13 presented with each item, including any new items suggested during round 1, and again express the  
14 extent to which they agree with the inclusion of the item in the TRIPOD-AI checklist or PROBAST-AI  
15 tool, considering the structured feedback to inform their responses. Participants who were invited to  
16 participate in round 1, but who did not respond will be invited to participate in round 2, and will be  
17 presented with an anonymised summary of the group ratings. Items that reached a high-level of  
18 agreement (scoring 4 or 5) in round 1 ( $\geq 70\%$ ) will be presented for information purposes only, with  
19 no voting on these items, though a free-text box will be provided for any comments. A third Delphi  
20 round will be used if deemed necessary by the Executive Committee.  
21  
22  
23  
24  
25  
26  
27  
28  
29

### 30 **Results from the Delphi survey**

31 Item scores will be summarised for the entire panel as a whole, as appropriate (e.g., frequency and  
32 proportions across the rating categories) accompanied by a narrative summary of findings, comments,  
33 and suggestions. Results from both rounds of the survey will be discussed by the Executive Committee.  
34 For items where there was no consensus following the second Delphi found will be discussed by the  
35 Executive Committee, and will be considered for discussion at the subsequent consensus meeting.  
36  
37  
38  
39  
40  
41

### 42 **Stage 3 – Consensus meeting**

43 Two virtual consensus meetings (separately for TRIPOD-AI and PROBAST-AI), both spread over 2 days,  
44 will be held with the objective of discussing the results from the Delphi exercise and finalising items  
45 to be included in the reporting guideline and risk of bias tool. The composition of the consensus group  
46 will reflect the diversity of the key stakeholders addressed above. Key experts participating in the  
47 Delphi exercise will be considered to participate in the consensus meeting. We will also consider  
48 inviting experts who did not contribute to the Delphi to participate in the consensus. A total of around  
49 25-30 international participants are expected to contribute to the virtual consensus meeting.  
50  
51  
52  
53  
54  
55  
56

### 57 **Procedure**



1  
2  
3 The agenda and any material (e.g., results from the systematic reviews and Delphi) for the consensus  
4 meeting will be prepared by the Executive Committee and will be shared with attendees in advance.  
5  
6 Members of the Executive Committee will facilitate a structured discussion on the rationale behind  
7  
8 each item identified in the Delphi exercise. Consensus meeting participants will then be given the  
9  
10 opportunity to discuss each item (reporting item for TRIPOD-AI and signalling question for PROBAST-  
11  
12 AI), and vote on each item. The decision to retain an item in the TRIPOD-AI and PROBAST-AI will be  
13  
14 based on achieving at least 70% support from the consensus meeting participants. The group will  
15  
16 agree on the draft list of reporting items for the final TRIPOD-AI extension and PROBAST-AI tool.  
17  
18 Specific item wording will not be discussed during the meeting, though participants can suggest and  
19  
20 the group to agree on general intent and meaning of the item. Plans for dissemination will be  
21  
22 discussed at the end of the consensus meeting.

### 23 **Pilot testing**

24  
25 We will invite authors of machine learning prediction model studies in the medical domain, doctoral  
26  
27 students undertaking prediction model, machine learning courses or workshops, and peer reviewers  
28  
29 and editors of journals who frequently publish such prediction model studies, to pilot the use of a  
30  
31 draft version of the TRIPOD-AI checklist and PROBAST-AI tool. We will ask those who pilot the checklist  
32  
33 and tool whether the wording of items is ambiguous or difficult to interpret.

### 34 35 **Stage 4 – Development of the draft TRIPOD-AI statement, PROBAST-AI and Explanation &** 36 37 **Elaboration documents**

38  
39 The Executive Committee will lead the development of the TRIPOD-AI reporting guidance and  
40  
41 PROBAST-AI signalling questions based on the agreed list of items from the consensus meeting (stage  
42  
43 3). The Executive Committee will invite a subset of members from the consensus meeting (to form a  
44  
45 writing group) to help draft the Explanation & Elaboration paper.

46  
47  
48 The Executive Committee will reserve the right to update (that is remove or add) additional items to  
49  
50 the TRIPOD-AI checklist during the development of the TRIPOD-AI statement, if and as necessary (as  
51  
52 a result of the pilot testing).

53  
54  
55 For each of the TRIPOD-AI extension and the PROBAST-AI risk of bias tool, two manuscripts will be  
56  
57 developed; (1) the Statement paper, presenting the checklist/tool and describing the process of how  
58  
59 it was developed and (2) an Explanation & Elaboration paper. The Explanation & Elaboration papers  
60

1  
2  
3 will outline the rationale of the reporting items (TRIPOD-AI) and signalling questions (PROBAST-AI),  
4 examples of good reporting (TRIPOD-AI) and examples of how to use PROBAST-AI. Drafts of the papers  
5 will be circulated to all participants of the consensus meeting for their comments.  
6  
7  
8  
9

### 10 **Stage 5 – Guideline dissemination**

11 The dissemination strategy will be informed by discussions at the consensus meeting. We will aim to  
12 seek simultaneous publication in key journals to target different readerships. To increase visibility and  
13 aid uptake, the TRIPOD-AI checklist and PROBAST-AI tool will be published open access, and made  
14 available on the TRIPOD website along with other TRIPOD extensions ([www.tripod-statement.org](http://www.tripod-statement.org)),  
15 and on the PROBAST website ([www.probast.org](http://www.probast.org)) respectively, as well on the PROGRESS website  
16 ([www.prognosisresearch.com](http://www.prognosisresearch.com)). The TRIPOD-AI extension will be indexed on the EQUATOR website  
17 ([www.equator-network.org](http://www.equator-network.org)). Social media will be used to help disseminate the extension. The  
18 Executive Committee will (and consensus participants will be encouraged to) publicise the TRIPOD-AI  
19 statement and PROBAST-AI tool at key conferences and courses.  
20  
21  
22  
23  
24  
25  
26  
27  
28

### 29 **Publication plan**

30 It is envisaged that the following publications will arise from the TRIPOD-AI and PROBAST-AI initiative:

- 31 • Publication 1: Study protocol
  - 32 • Publication 2: Systematic review protocol (with registration on PROSPERO)
  - 33 • Publication 3 & 4: Systematic reviews
  - 34 • Publication 5 & 6: TRIPOD-AI statement and the Explanation and Elaboration paper
  - 35 • Publication 7 & 8: PROBAST-AI tool and the Explanation and Elaboration paper
- 36  
37  
38  
39  
40  
41

### 42 **Conclusion**

43 The number of prediction model studies using machine learning methods is rapidly increasing,  
44 including developed, validated or updated prediction models. Ensuring that key details are reported  
45 is important so that readers can evaluate the study quality, and interpret its findings including the  
46 developed, validated or updated prediction model to enhance their uptake in subsequent research  
47 (e.g. validation studies), evidence synthesis projects (e.g. systematic reviews of prediction models),  
48 and in daily practice by healthcare professionals, patients or citizens. We anticipate that TRIPOD-AI  
49 will help authors transparently report their study and help reviewers, editors, policy makers and end-  
50 users understand the methods and findings, and thereby reduce research waste. Similarly, we  
51 anticipate PROBAST-AI will help researchers, clinicians, systematic reviewers and policy-makers  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 critically appraise the design, conduct and analysis of machine learning based prediction model  
4 studies.  
5  
6  
7

### 8 **Patient and Public Involvement**

9  
10 No patients or members of the public were involved in the development of this protocol. Patient and  
11 public involvement is planned for the virtual consensus meeting.  
12  
13

### 14 **Ethics and Dissemination**

15  
16 Ethical approval has been granted by the Central University Research Ethics Committee (CUREC),  
17 University of Oxford on 10-December-2020 (R73034/RE001). Findings from this study will be  
18 disseminated through peer review publications.  
19  
20  
21

### 22 **Contributor statement**

23  
24 Gary S. Collins, Paula Dhiman, Constanza L. Andaur Navarro, Jie Ma, Lotty Hooft, Johannes B. Reitsma,  
25 Patricia Logullo, Andrew L. Beam, Lily Peng, Ben Van Calster, Maarten van Smeden, Richard D. Riley,  
26 Karel G.M. Moons were involved in the planning and design of the study. Gary Collins drafted the  
27 manuscript with all authors contributing to the writing.  
28  
29  
30  
31

### 32 **Competing interests**

33  
34 The authors declare no competing interests.  
35  
36  
37

### 38 **Data sharing statement**

39  
40 There is no data to share.  
41  
42

### 43 **Funding**

44  
45 This research was supported by Health Data Research UK, an initiative funded by UKResearch and  
46 Innovation, Department of Health and Social Care (England) and the devolved administrations, and  
47 leading medical research charities, Cancer Research UK programme grant (C49297/A27294), the NIHR  
48 Biomedical Research Centre, Oxford, and the Netherlands Organisation for Scientific Research. The  
49 funders have no role in the development of this protocol and will not have a role in the data collection,  
50 analyses, interpretation of the data, and publication of the findings.  
51  
52  
53  
54  
55

### 56 **References**

57  
58 1. Collins GS, Reitsma JB, Altman DG, Moons KGM. Transparent Reporting of a multivariable prediction model  
59 for Individual Prognosis Or Diagnosis (TRIPOD): The TRIPOD Statement. *Ann Intern Med.* 2015;162:55–63.  
60

2. Moons KG, Kengne AP, Woodward M, Royston P, Vergouwe Y, Altman DG, et al. Risk prediction models: I. Development, internal validation, and assessing the incremental value of a new (bio)marker. *Heart*. 2012;98:683–90.
3. Collins GS, Mallett S, Omar O, Yu LM. Developing risk prediction models for type 2 diabetes: a systematic review of methodology and reporting. *BMC Med*. 2011;9:103.
4. Collins GS, de Groot JA, Dutton S, Omar O, Shanyinde M, Tajar A, et al. External validation of multivariable prediction models: a systematic review of methodological conduct and reporting. *BMC Med Res Meth*. 2014;14:40.
5. Bouwmeester W, Zuithoff NP, Mallett S, Geerlings MI, Vergouwe Y, Steyerberg EW, et al. Reporting and methods in clinical prediction research: a systematic review. *PLoS Med*. 2012;9:e1001221.
6. Mallett S, Royston P, Dutton S, Waters R, Altman DG. Reporting methods in studies developing prognostic models in cancer: a review. *BMC Med*. 2010;8:20.
7. Chalmers I, Glasziou P. Avoidable waste in the production and reporting of research evidence. *Lancet*. 2009;374:86–9.
8. Moons KGM, Altman DG, Reitsma JB, Ioannidis JPA, Macaskill P, Steyerberg EW, et al. Transparent Reporting of a multivariable prediction model for Individual Prognosis Or Diagnosis (TRIPOD): Explanation and Elaboration. *Ann Intern Med*. 2015;162:W1–73.
9. Yu KH, Beam AL, Kohane IS. Artificial intelligence in healthcare. *Nat Biomed Eng*. 2018;2:719–31.
10. Beam AL, Kohane IS. Big Data and Machine Learning in Health Care. *JAMA*. 2018.
11. Ghassemi M, Naumann T, Schulam P, Beam AL, Chen IY, Ranganath R. Practical guidance on artificial intelligence for health-care data. *Lancet Digit Health*. 2019;1:e157–9.
12. Beam AL, Manrai AK, Ghassemi M. Challenges to the Reproducibility of Machine Learning Models in Health Care. *JAMA*. 2020. doi:10.1001/jama.2019.20866.
13. Sendak M, D’Arcy J, Kashyap S, Gao M, Nichols M, Corey K, et al. A Path for Translation of Machine Learning Products into Healthcare Delivery. *EMJ Innov*. 2020. doi:10.33590/emjinnov/19-00172.
14. Wiens J, Saria S, Sendak M, Ghassemi M, Liu VX, Doshi-Velez F, et al. Do no harm: a roadmap for responsible machine learning for health care. *Nat Med*. 2019. doi:10.1038/s41591-019-0548-6.
15. Wynants L, Van Calster B, Collins GS, Riley RD, Heinze G, Schuit E, et al. Prediction models for diagnosis and prognosis of covid-19: systematic review and critical appraisal. *BMJ*. 2020;369:m1328.
16. Breiman L. Statistical modeling: the two cultures. *Stat Sci*. 2001;16:199–231.
17. Shillan D, Sterne JAC, Champneys A, Gibbison B. Use of machine learning to analyse routinely collected intensive care unit data: a systematic review. *Crit Care*. 2019;23:284.
18. Christodoulou E, Ma J, Collins GS, Steyerberg EW, Verbakel JY, van Calster B. A systematic review shows no performance benefit of machine learning over logistic regression for clinical prediction models. *J Clin Epidemiol*. 2019.
19. Collins GS, Moons KGM. Reporting of artificial intelligence prediction models. *The Lancet*. 2019;393:1577–9.
20. Wolff RF, Moons KGM, Riley RD, Whiting PF, Westwood M, Collins GS, et al. PROBAST: A Tool to Assess the Risk of Bias and Applicability of Prediction Model Studies. *Ann Intern Med*. 2019;170:51–8.

- 1  
2  
3 21. Moons KGM, Wolff RF, Riley RD, Whiting PF, Westwood M, Collins GS, et al. PROBAST: A Tool to Assess Risk  
4 of Bias and Applicability of Prediction Model Studies: Explanation and Elaboration. *Ann Intern Med*.  
5 2019;170:W1–33.  
6  
7 22. Liu Y, Chen P-HC, Krause J, Peng L. How to Read Articles That Use Machine Learning: Users' Guides to the  
8 Medical Literature. *JAMA*. 2019;322:1806.  
9  
10 23. Faes L, Liu X, Wagner SK, Fu DJ, Balaskas K, Sim DA, et al. A Clinician's Guide to Artificial Intelligence: How  
11 to Critically Appraise Machine Learning Studies. *Transl Vis Sci Technol*. 2020;9:7.  
12  
13 24. Moons KGM, Altman DG, Vergouwe Y, Royston P. Prognosis and prognostic research: application and  
14 impact of prognostic models in clinical practice. *BMJ*. 2009;338:b606.  
15  
16 25. Sounderajah V, Ashrafian H, Aggarwal R, De Fauw J, Denniston AK, Greaves F, et al. Developing specific  
17 reporting guidelines for diagnostic accuracy studies assessing AI interventions: The STARD-AI Steering Group.  
18 *Nat Med*. 2020. doi:10.1038/s41591-020-0941-1.  
19  
20 26. Moher D, Schulz KF, Simera I, Altman DG. Guidance of developers of health research reporting guidelines.  
21 *PLoS Med*. 2010;7:e1000217.  
22  
23 27. Heus P, Damen JAAG, Pajouheshnia R, Scholten RJPM, Reitsma JB, Collins GS, et al. Poor reporting of  
24 multivariable prediction model studies: towards a targeted implementation strategy of the TRIPOD statement.  
25 *BMC Med*. 2018;16.  
26  
27 28. Liu X, Faes L, Kale AU, Wagner SK, Fu DJ, Bruynseels A, et al. A comparison of deep learning performance  
28 against health-care professionals in detecting diseases from medical imaging: a systematic review and meta-  
29 analysis. *Lancet Digit Health*. 2019;1:e271–97.  
30  
31 29. Boel A, Navarro-Compán V, Landewé R, van der Heijde D. Two different invitation approaches for  
32 consecutive rounds of a Delphi survey led to comparable final outcome. *J Clin Epidemiol*. 2021;129:31–9.  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60